 |
|
|
| |
Interim analysis of An INTERFERON (IFN)- AND RIBAVIRIN (RBV)-FREE REGIMEN of DACLATASVIR (DCV), ASUNAPREVIR (ASV), AND BMS-791325 IN TREATMENT-NAIVE, HEPATITIS C VIRUS GENOTYPE 1-INFECTED PATIENTS
|
| |
| |
Reported by Jules Levin
APASL Liver Week 2013
Asian Pacific Association for the Study of the Liver
Singapore, June 6-10, 2013
Gregory T. Everson*1, Karen D. Sims2, Maribel Rodriguez-Torres3, Christophe Hezode4, Eric Lawitz5, Marc Bourliere6, Veronique Loustaud-Ratti7, Vinod Rustgi8, Howard Schwartz9, Harvey Tatum10, Patrick Marcellin11, Stanislas Pol12, Paul J. Thuluvath13, Timothy Eley2, Xiaodong Wang2, Shu-Pang Huang14, Fiona McPhee15, Megan Wind-Rotolo14, Ellen Chung2, Claudio Pasquinelli2, Dennis M. Grasela2, David F. Gardiner2
1University of Colorado Denver, Aurora, CO, USA; 2Bristol-Myers Squibb, Hopewell, NJ, USA; 3Fundacion de Investigacion, San Juan, Puerto Rico; 4CHU Henri Mondor, Service d'Hepato-Gastroenterologie, Creteil, France; 5Alamo Medical Research, San Antonio, TX, USA; 6Hopital Saint Joseph, Service d'Hepato-Gastroenterologie, Marseille, France; 7University Hospital of Limoges, Limoges, France; 8Metropolitan Research, Arlington, VA, USA; 9Miami Research Associates, South Miami, FL, USA; 10Options Health Research, Tulsa, OK, USA; 11Hopital Beaujon, Clichy, France; 12Universite Paris Descartes, INSERM U1610 and Liver Unit, Hopital Cochin, Paris, France; 13Mercy Medical Center, Baltimore, MD, USA; 14Bristol-Myers Squibb, Princeton, NJ, USA; 15Bristol-Myers Squibb, Wallingford, CT, USA
|
| |
|
|
|
|
|
